Literature DB >> 24372914

Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.

Simon R W Stott1, Roger A Barker1.   

Abstract

The 6-hydroxydopamine (6-OHDA) neurotoxic lesion of the midbrain dopamine (DA) system is one of the most widely used techniques for modelling Parkinson's disease in rodents. The majority of studies using this approach, however, largely limit their analysis to lesioning acutely, and looking at behavioural deficits and the number of surviving tyrosine hydroxylase (TH)-stained cells in the midbrain. Here we have analysed additional characteristics that occur following intrastriatal delivery of 6-OHDA, providing better understanding of the neurodegenerative process. Female C57/Black mice were given lesions at 10 weeks old, and killed at several different time points postoperatively (3 and 6 h, 1, 3, 6, 9 and 12 days). While the detrimental effect of the toxin on the TH+ fibres in the striatum was immediate, we found that the loss of TH+ dendritic fibres, reduction in cell size and intensity of TH expression, and eventual reduction in the number of TH+ neurons in the substantia nigra was delayed for several days post-surgery. We also investigated the expression of various transcription factors and proteins expressed by midbrain DA neurons following lesioning, and observed changes in the expression of Aldh1a1 (aldehyde dehydrogenase 1 family, member A1) as the neurodegenerative process evolved. Extracellularly, we looked at microglia and astrocytes in reaction to the 6-OHDA striatal lesion, and found a delay in their response and proliferation in the substantia nigra. In summary, this work highlights aspects of the neurodegenerative process in the 6-OHDA mouse model that can be applied to future studies looking at therapeutic interventions.
© 2013 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  6-OHDA; Parkinson's disease; dopamine; neurodegeneration; substantia nigra

Mesh:

Substances:

Year:  2013        PMID: 24372914     DOI: 10.1111/ejn.12459

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  44 in total

1.  Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model.

Authors:  Christopher A Lieu; Colleen M Dewey; Shankar J Chinta; Anand Rane; Subramanian Rajagopalan; Sean Batir; Yong-Hwan Kim; Julie K Andersen
Journal:  Brain Res       Date:  2014-10-27       Impact factor: 3.252

2.  Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  D P Ferrari; M Bortolanza; E A Del Bel
Journal:  Neurotox Res       Date:  2021-03-09       Impact factor: 3.911

Review 3.  Estrogens, Neuroinflammation, and Neurodegeneration.

Authors:  Alessandro Villa; Elisabetta Vegeto; Angelo Poletti; Adriana Maggi
Journal:  Endocr Rev       Date:  2016-05-19       Impact factor: 19.871

4.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

Review 5.  Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.

Authors:  Edna Grünblatt; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2014-10-09       Impact factor: 3.575

6.  ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2015-07-30       Impact factor: 5.590

7.  CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Authors:  Fabrine Sales Massafera Tristão; Márcio Lazzarini; Sabine Martin; Majid Amar; Walter Stühmer; Frank Kirchhoff; Lucas Araújo Caldi Gomes; Laurance Lanfumey; Rui D Prediger; Julia E Sepulveda; Elaine A Del-Bel; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2015-09-24       Impact factor: 3.911

Review 8.  Vagal neurocircuitry and its influence on gastric motility.

Authors:  R Alberto Travagli; Laura Anselmi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-05-25       Impact factor: 46.802

Review 9.  NF-κB-Mediated Neuroinflammation in Parkinson's Disease and Potential Therapeutic Effect of Polyphenols.

Authors:  Saumitra Sen Singh; Sachchida Nand Rai; Hareram Birla; Walia Zahra; Aaina Singh Rathore; Surya Pratap Singh
Journal:  Neurotox Res       Date:  2019-12-10       Impact factor: 3.911

10.  Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; S Bulnes; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.